Pre-made Glembatumumab Vedotin benchmark antibody (Whole mAb ADC, anti-GPNMB therapeutic antibody, Anti-HGFIN/NMB/PLCA3 Antibody) for drug discovery and mechanism of action (MOA) research

Cat:GMP-Bios-INN-856
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
SKU GMP-Bios-INN-856 Category Tag

Product Details

Pre-made Glembatumumab Vedotin benchmark antibody (Whole mAb ADC, anti-GPNMB therapeutic antibody, Anti-HGFIN/NMB/PLCA3 Antibody) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.

Glembatumumab vedotin (also known as CDX-11 and CR11-vcMMAE) is an antibody-drug conjugate (ADC) that targets cancer cells expressing transmembrane glycoprotein NMB (GPNMB).

Products Name (INN Index)

Pre-Made Glembatumumab Vedotin Biosimilar, Whole Mab Adc, Anti-Gpnmb Antibody: Anti-HGFIN/NMB/PLCA3 therapeutic antibody Drug Conjugate

INN Name

glembatumumab vedotin

Target

GPNMB

Format

Whole mAb ADC

Derivation

Human

Species Reactivity

Human

CH1 Isotype

IgG2 – kappa

VD LC

IgG2 – kappa

Highest_Clin_Trial (Jan '20)

NA

Est. Status

NA

100% SI Structure

NA

99% SI Structure

NA

95-98% SI Structure

NA

Year Proposed

NA

Companies

Celldex Therapeutics,?Inc. (Needham MA USA)

Conditions Approved

NA

Conditions Active

NA

Conditions Discontinued

NA

Development Tech

Abgenix's XenoMouse?

Previous Name

NA

Gm Offical Target Name

GPNMB

Package

, ,

Genemeidi Omicron Variant Products
test
Previous
Next
This site uses cookies to offer you a better browsing experience. By browsing this website, you agree to our use of cookies.